Literature DB >> 33287312

Effect of Heme Oxygenase-1 on Melanoma Development in Mice-Role of Tumor-Infiltrating Immune Cells.

Halina Was1,2, Tomasz Cichon3, Ryszard Smolarczyk3, Bozena Lackowska4, Agnieszka Mazur-Bialy5, Magdalena Mazur1, Agata Szade1, Pawel Dominik1, Milena Mazan1, Jerzy Kotlinowski1, Anna Zebzda6, Anna Kusienicka1, Claudine Kieda2, Jozef Dulak1, Alicja Jozkowicz1.   

Abstract

OBJECTIVE: Heme oxygenase-1 (HO-1) is a cytoprotective, proangiogenic and anti-inflammatory enzyme that is often upregulated in tumors. Overexpression of HO-1 in melanoma cells leads to enhanced tumor growth, augmented angiogenesis and resistance to anticancer treatment. The effect of HO-1 in host cells on tumor development is, however, hardly known. METHODS AND
RESULTS: To clarify the effect of HO-1 expression in host cells on melanoma progression, C57BL/6xFvB mice of different HO-1 genotypes, HO-1+/+, HO-1+/-, and HO-1-/-, were injected with the syngeneic wild-type murine melanoma B16(F10) cell line. Lack of HO-1 in host cells did not significantly influence the host survival. Nevertheless, in comparison to the wild-type counterparts, the HO-1+/- and HO-1-/- males formed bigger tumors, and more numerous lung nodules; in addition, more of them had liver and spleen micrometastases. Females of all genotypes developed at least 10 times smaller tumors than males. Of importance, the growth of primary and secondary tumors was completely blocked in HO-1+/+ females. This was related to the increased infiltration of leukocytes (mainly lymphocytes T) in primary tumors.
CONCLUSIONS: Although HO-1 overexpression in melanoma cells can enhance tumor progression in mice, its presence in host cells, including immune cells, can reduce growth and metastasis of melanoma.

Entities:  

Keywords:  cancer; female; heme oxgenase-1 (HO-1); melanoma; tumor-infiltrating immune cells

Year:  2020        PMID: 33287312     DOI: 10.3390/antiox9121223

Source DB:  PubMed          Journal:  Antioxidants (Basel)        ISSN: 2076-3921


  4 in total

1.  HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAFV600E Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia.

Authors:  Anna Lisa Furfaro; Giulia Loi; Caterina Ivaldo; Mario Passalacqua; Gabriella Pietra; Giovanni Enrico Mann; Mariapaola Nitti
Journal:  Antioxidants (Basel)       Date:  2022-06-14

2.  Heme Oxygenase-1 Has a Greater Effect on Melanoma Stem Cell Properties Than the Expression of Melanoma-Initiating Cell Markers.

Authors:  Anna Kusienicka; Karolina Bukowska-Strakova; Maciej Cieśla; Witold Norbert Nowak; Iwona Bronisz-Budzyńska; Agnieszka Seretny; Monika Żukowska; Mateusz Jeż; Rościsław Krutyhołowa; Hevidar Taha; Neli Kachamakova-Trojanowska; Halina Waś; Claudine Kieda; Alicja Józkowicz
Journal:  Int J Mol Sci       Date:  2022-03-25       Impact factor: 5.923

3.  Determination of CCL2 / MCP-1 levels in the serum of children with melanocytic nevus in the postoperative period after using different methods of surgical treatment.

Authors:  Oleh Pasichnyk; Viktor Konoplitskyi; Yurii Korobko; Yuliana Babina; Dmytro Dmyrtriiev; Oleksandr Nazarchuk
Journal:  Acta Biomed       Date:  2022-05-11

4.  High Hemin Concentration Induces Escape from Senescence of Normoxic and Hypoxic Colon Cancer Cells.

Authors:  Agata Borkowska; Aleksandra Olszewska; Weronika Skarzynska; Marta Marciniak; Maciej Skrzeszewski; Claudine Kieda; Halina Was
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.